智通财经APP获悉，招银国际发布研报称，首次覆盖药明合联(02268)，给予“买入”评级，目标价74港元。该行预计，公司2025至27年的收入将同比增长45.7%、35.7%及30.9%，经调整净利润则同比增长40%、32.4%及30.8%。
该行指出，药明合联已成为全球XDC外包服务产业的领导者，公司可在其无锡基地提供“一站式”XDC研发和生产服务，并正在建造其新加坡基地。公司的项目数量快速增长，截至今年上半年已拥有19个临床三期和11个PPQ阶段的项目，后期及商业化项目将支撑公司未来持续增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.